[Image courtesy of Q’Apel Medical]

[图片由Q'Apel Medical提供]

Q’Apel Medical

Q'Apel医疗

today announced it received CE mark certification for its Armadillo SelectFlex Neurovascular Access System.

今天宣布其Armadillo SelectFlex神经血管接入系统获得CE标志认证。

The 7F system uses the company’s SelectFlex Technology and is indicated for introducing interventional devices into the neurovasculature.

7F系统使用该公司的SelectFlex技术，用于将介入设备引入神经血管系统。

“Neurovascular access can be extremely challenging. The tortuous anatomy requires flexibility to navigate the tight twists and turns, however, flexible access catheters tend to lack the support and stability required for device delivery once positioned,” said Dr. Pascal Jabbour, The Angela and Richard T.

“神经血管通路可能非常具有挑战性。曲折的解剖结构需要灵活才能驾驭紧张的曲折，然而，灵活的通路导管往往缺乏定位后设备输送所需的支持和稳定性，”Pascal Jabbour博士，Angela和Richard T。

Clark Distinguished Professor of Neurological Surgery and Radiology, Division Chief of Neurovascular Surgery & Endovascular Neurosurgery at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. “Armadillo provides a one-and-done solution that simplifies access procedures. It is designed to place full control in the hands of the operator as it allows users to transform the catheter from highly trackable to highly supportive as needed throughout the procedure with the simple injection or withdrawal of just 0.2cc of saline.”.

宾夕法尼亚州费城托马斯杰斐逊大学医院神经外科和放射学杰出教授、神经血管外科和血管内神经外科科长克拉克。“Armadillo提供了一个一劳永逸的解决方案，简化了访问程序。它旨在将完全控制权交给操作员，因为它允许用户在整个过程中根据需要将导管从高度可追踪转变为高度支持，只需注射或取出0.2摄氏度的盐水。”。

The device’s low-profile 7F catheter allows for a biaxial approach to help speed up delicate interventions and reduce the cost of conventional tri-axial configurations, according to the company.

该公司表示，该设备的低剖面7F导管允许双轴方法，以帮助加速精细干预并降低传统三轴配置的成本。

“The Armadillo Neurovascular Access System with SelectFlex™ Technology addresses the shortcomings of currently available neurovascular access catheters. We believe it provides a novel option that allows hospitals to standardize device usage, decrease inventory constraints and reduce cost per procedure,” CEO Jodie Fam said in a news release.

首席执行官朱迪·法姆（JodieFam）在新闻稿中表示：“采用SelectFlex™技术的犰狳神经血管通路系统解决了目前可用的神经血管通路导管的缺点。我们相信它提供了一种新的选择，使医院能够标准化设备使用，减少库存限制，降低每个程序的成本。”。

“I thank our incredible team for their efforts to achieve this critical milestone. We look forward to building upon Armadillo’s U.S. commercial success as we prepare to expand our international portfolio and deliver this meaningful solution to the European market, and others, in the coming months.”.

“我感谢我们令人难以置信的团队为实现这一关键里程碑所做的努力。我们期待着在Armadillo在美国取得商业成功的基础上再接再厉，在未来几个月内，我们将扩大我们的国际投资组合，并向欧洲市场和其他市场提供这一有意义的解决方案。”。